Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus

Biomaterials

Volumn 32, Issue 26, 2011, Pages 6285-6290

  Lai, Samuel K ^a,d   Suk, Jung Soo ^b   Pace, Amanda ^a   Wang, Ying Ying ^b   Yang, Ming ^b   Mert, Olcay ^a   Chen, Jeane ^a   Kim, Jean ^b   Hanes, Justin ^a,b,c  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d University of North Carolina   (United States)

Author keywords

Drug delivery; Mucus penetrating particles; Particle tracking; PEG; Polymer; Sinusitis

Indexed keywords

AVERAGE SPEED; DIFFUSION RATE; DRUG CARRIER; EFFECTIVE THERAPY; ENDOSCOPIC SINUS SURGERY; EPITHELIAL CELLS; HUMAN MUCUS; INFLAMMATORY CONDITIONS; MUCUS-PENETRATING PARTICLES; NANOMEDICINES; NASAL POLYPS; PARTICLE TRACKING; PLURONICS; POLY-LACTIDE-CO-GLYCOLIDE; POLYSTYRENE NANOPARTICLES; SINUSITIS; TWO-MATERIALS; UNCOATED POLYSTYRENES;

DIFFUSION COATINGS; DRUG DELIVERY; GLYCOLS; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYSTYRENES;

BODY FLUIDS;

ANTIBIOTIC AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; DRUG CARRIER; MACROGOL; MUCOLYTIC AGENT; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYSTYRENE; WATER;

ARTICLE; BIODEGRADATION; CHRONIC DISEASE; DIFFUSION; ENDOSCOPIC SINUS SURGERY; HUMAN; HUMAN TISSUE; MUCUS; NANOMEDICINE; NOSE POLYP; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RHINOSINUSITIS; SAFETY;

DRUG CARRIERS; HUMANS; MUCUS; NANOPARTICLES; NASAL POLYPS; POLOXAMER; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; SINUSITIS;

EID: 79959868168     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.05.008     Document Type: Article

References (42)

1. Dalton P. Olfaction and anosmia in rhinosinusitis. Current Allergy and Asthma Reports 2004, 4:230-236.
2. Benninger M.S., Ferguson B.J., Hadley J.A., Hamilos D.L., Jacobs M., Kennedy D.W., et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngology-Head & Neck Surgery 2003, 129:S1-S32.
3. Ponikau J. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. The Journal of Allergy and Clinical Immunology 2005, 116:362-369.
4. Heinecke L., Proud D., Sanders S., Schleimer R.P., Kim J. Induction of B7-H1 and B7-DC expression on airway epithelial cells by the toll-like receptor 3 agonist double-stranded RNA and human rhinovirus infection: in vivo and in vitro studies. The Journal of Allergy and Clinical Immunology 2008, 121:1155-1160.
5. Ponikau J.U., Sherris D.A., Kephart G.M., Kern E.B., Gaffey T.A., Tarara J.E., et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma?. The Journal of Allergy and Clinical Immunology 2003, 112:877-882.
6. Raviv J.R., Kern R.C. Chronic rhinosinusitis and olfactory dysfunction. Advances in Oto-rhino-laryngology 2006, 63:108-124.
7. Mott A.E., Cain W.S., Lafreniere D., Leonard G., Gent J.F., Frank M.E. Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. Archives of Otolaryngology-Head & Neck Surgery 1997, 123:367-372.
8. Dykewicz M.S., Fineman S., Skoner D.P., Nicklas R., Lee R., Blessing-Moore J., et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol 1998, 81:478-518. American Academy of Allergy, Asthma, and Immunology.
9. LaVan D.A., McGuire T., Langer R. Small scale systems for in vivo drug delivery. Nature Biotechnology 2003, 21:1184-1191.
10. Rosen H., Abribat T. The rise and rise of drug delivery. Nature Reviews Drug Discovery 2005, 4:381-385.
11. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Advanced Drug Delivery Reviews 2009, 61:158-171.
12. Cone R. Mucus. Mucosal immunlogy 1999, 43-64. Academic Press, San Diego. 3 ed. E. Michael, W.S. Lamm, J.R. McGhee, L. Mayer, J. Mestecky, J. Bienenstock (Eds.).
13. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proceedings of the National Academy of Sciences United States of America 2007, 104:1482-1487.
14. Dawson M., Wirtz D., Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. Journal of Biological Chemistry. 2003, 278:50393-50401.
15. Lai S.K., Wang Y.Y., Wirtz D., Hanes J. Micro- and macrorheology of mucus. Advanced Drug Delivery Reviews 2009, 61:86-100.
16. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
17. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angewandte Chemie International Edition 2008, 47:9726-9729.
18. Suh J., Dawson M., Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Advanced Drug Delivery Reviews 2005, 57:63-78.
19. Suk J.S., Suh J., Lai S.K., Hanes J. Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons. Experimental Biology and Medicine 2007, 232:461-469.
20. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharmaceutical Research 1999, 16:1114-1118.
21. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proceedings of the National Academy of Sciences United States of America 2010, 107:598-603.
22. Amsden B. Solute diffusion within hydrogels. Mechanisms and models. Macromolecules 1998, 31:8382-8395.
23. Amsden B. An obstruction-scaling model for diffusion in homogeneous hydrogels. Macromolecules 1999, 32:874-879.
24. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophysical Journal 2001, 81:1930-1937.
25. Shen H., Hu Y., Saltzman W.M. DNA diffusion in mucus: effect of size, topology of DNAs, and transfection reagents. Biophysical Journal 2006, 91:639-644.
26. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 1997, 28:5-24.
27. Ignatius A.A., Claes L.E. In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). Biomaterials 1996, 17:831-839.
28. Visscher G.E., Robison R.L., Maulding H.V., Fong J.W., Pearson J.E., Argentieri G.J. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. Journal of Biomedical Materials Research 1985, 19:349-365.
29. Inactive ingredient search for approved drug products, "poloxamer" 2011, U.S. Food and Drug Administration.
30. Yang M., Lai S.K., Wang Y.Y., Zhong W., Happe C., Zhang M., et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angewandte Chemie International Edition 2011, 50:2597-2600.
31. Crawford E.D., Sartor O., Chu F., Perez R., Karlin G., Garrett J.S. A 12-month clinical study of LA-2585 (45.0 MG): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. The Journal of Urology 2006, 175:533-536.
32. Kim T.S., Klimpel H., Fiehn W., Eickholz P. Comparison of the pharmacokinetic profiles of two locally administered doxycycline gels in crevicular fluid and saliva. Journal of Clinical Periodontology 2004, 31:286-292.
33. Donaldson D., Gelskey S.C., Landry R.G., Matthews D.C., Sandhu H.S. A placebo-controlled multi-centred evaluation of an anaesthetic gel (Oraqix) for periodontal therapy. Journal of Clinical Periodontology 2003, 30:171-175.
34. Emanuele R.M. FLOCOR: a new anti-adhesive, rheologic agent. Expert Opinion on Investigational Drugs 1998, 7:1193-1200.
35. Na-Bangchang K., Karbwang J., Palacios P.A., Ubalee R., Saengtertsilapachai S., Wernsdorfer W.H. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology 2000, 55:743-748.
36. Thiboutot D.M., Shalita A.R., Yamauchi P.S., Dawson C., Kerrouche N., Arsonnaud S., et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Archives of Dermatology 2006, 142:597-602.
37. McGinity J.W., O'Donnell P.B. Preparation of microspheres by the solvent evaporation technique. Advanced Drug Delivery Reviews 1997, 28:25-42.
38. Lai S.K., Wang Y.Y., Cone R., Wirtz D., Hanes J. Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS ONE 2009, 4:e4294.
39. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. Journal of Internal Medicine 2007, 261:5-16.
40. Wang X., Kim J., McWilliams R., Cutting G.R. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Archives of Otolaryngology-Head & Neck Surgery 2005, 131:237-240.
41. Wang X., Moylan B., Leopold D.A., Kim J., Rubenstein R.C., Togias A., et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. Jama 2000, 284:1814-1819.
42. Suk J.S., Lai S.K., Boylan N.J., Dawson M.R., Boyle M.P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 2011, 6:365-375.